세계의 오피오이드 유발성 호흡 억제 시장 규모 : 제품 유형별, 최종사용자별, 지역별 예측(2022-2028년)

Global Opioid-Induced Respiratory Depression Market is valued approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2028. Opioid-Induced Respiratory Depression can be defined as breathing difficulties caused due to overdose of opioids. Opioids are a class of drugs that include the illegal drug heroin, synthetic opioids such as fentanyl, and pain relievers available legally by prescription, such as oxycodone, hydrocodone, codeine, morphine etc. The rising incidences of opioid use and drug overdose and increasing prevalence of hypoventilation syndrome as well as recent product launches and favorable government policies are accelerating the global market demand. For instance, according to World Health Organization - as of 2021, Worldwide drug use caused 500,000 deaths. More than 70% of these deaths are caused due to opioids, whereas 30% of deaths caused by overdose of opioids. Furthermore, In August 2021, FDA approved use of higher dose naloxone hydrochloride nasal spray for treatment of opioid overdose. Moreover, In December 2021, Switzerland based Sandoz launched authorized generic version of Narcan®(naloxone hydrochloride) Nasal Spray in United States. This new drug is intended to reverse opioid overdose. This spay would be available through retail pharmacies and hospitals . Also, growing number of rehabilitation activities and rising R&D activities towards development of new therapeutics solutions are anticipated to act as a catalyzing factor for the market demand during the forecast period. However, high treatment cost associated with respiratory depression impede the growth of the market over the forecast period of 2022-2028.

The key regions considered for the global Opioid-Induced Respiratory Depression Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to the growing prevalence of opioid-induced respiratory depression and presence of leading market players. Whereas, Asia Pacific is anticipated to exhibit a significant growth rate over the forecast period 2022-2028. Factors such as rising pharmaceuticals sector and increasing number of rehabilitation centers in the region, would create lucrative growth prospects for the Opioid-Induced Respiratory Depression Market across the Asia Pacific region.

Major market players included in this report are:

Medtronic plc

Smiths Group

Masimo Corporation

Nihon Kohden Corporation

Covidien, GE Healthcare

Welch Allyn

Becton

Dickinson and Company

BioMed Jena GmbH

Hill-Rom, Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product Type

Pulse Oximeter

Capnographs

Audiometry

Integrated Delivery & Monitoring Devices

Acoustic Monitor

Radar Monitor

Bioimpedance Device

Inductance Plethysmograph

By End User

Hospital

Ambulatory Surgical Center

Specialty Clinic

Diagnostic Center

Others

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019, 2020

Base year - 2021

Forecast period - 2022 to 2028

Target Audience of the Global Opioid-Induced Respiratory Depression Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2028 (USD Million)
  • 1.2.1. Global Opioid-Induced Respiratory Depression Market, by Region, 2020-2028 (USD Million)
  • 1.2.2. Global Opioid-Induced Respiratory Depression Market, by Product Type, 2020-2028 (USD Million)
  • 1.2.3. Global Opioid-Induced Respiratory Depression Market, by End User, 2020-2028 (USD Million)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Opioid-Induced Respiratory Depression Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Scope of the Study
  • 2.2.2. Industry Evolution
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Opioid-Induced Respiratory Depression Market Dynamics

• 3.1. Opioid-Induced Respiratory Depression Market Impact Analysis (2020-2028)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Rising incidences of opioid use and drug overdose.
    • 3.1.1.2. Increasing prevalence of hypoventilation syndrome.
    • 3.1.1.3. Recent product launches and favourable government policies.
  • 3.1.2. Market Challenges
    • 3.1.2.1. High treatment cost associated with respiratory depression.
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Growing number of rehabilitation activities.
    • 3.1.3.2. Rising R&D activities towards development of new therapeutics solutions

Chapter 4. Global Opioid-Induced Respiratory Depression Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Force Model (2018-2028)
• 4.2. PEST Analysis
  • 4.2.1. Political
  • 4.2.2. Economical
  • 4.2.3. Social
  • 4.2.4. Technological
• 4.3. Investment Adoption Model
• 4.4. Analyst Recommendation & Conclusion
• 4.5. Top investment opportunity
• 4.6. Top winning strategies

Chapter 5. Risk Assessment: COVID-19 Impact

• 5.1.1. Assessment of the overall impact of COVID-19 on the industry
• 5.1.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Opioid-Induced Respiratory Depression Market, by Product Type

• 6.1. Market Snapshot
• 6.2. Global Opioid-Induced Respiratory Depression Market by Product Type, Performance - Potential Analysis
• 6.3. Global Opioid-Induced Respiratory Depression Market Estimates & Forecasts by Product Type 2018-2028 (USD Million)
• 6.4. Opioid-Induced Respiratory Depression Market, Sub Segment Analysis
  • 6.4.1. Pulse Oximeter
  • 6.4.2. Capnographs
  • 6.4.3. Audiometry
  • 6.4.4. Integrated Delivery & Monitoring Devices
  • 6.4.5. Acoustic Monitor
  • 6.4.6. Radar Monitor
  • 6.4.7. Bioimpedance Device
  • 6.4.8. Inductance Plethysmograph

Chapter 7. Global Opioid-Induced Respiratory Depression Market, by End User

• 7.1. Market Snapshot
• 7.2. Global Opioid-Induced Respiratory Depression Market by End User, Performance - Potential Analysis
• 7.3. Global Opioid-Induced Respiratory Depression Market Estimates & Forecasts by End User 2018-2028 (USD Million)
• 7.4. Opioid-Induced Respiratory Depression Market, Sub Segment Analysis
  • 7.4.1. Hospital
  • 7.4.2. Ambulatory Surgical Center
  • 7.4.3. Specialty Clinic
  • 7.4.4. Diagnostic Center
  • 7.4.5. Others

Chapter 8. Global Opioid-Induced Respiratory Depression Market, Regional Analysis

• 8.1. Opioid-Induced Respiratory Depression Market, Regional Market Snapshot
• 8.2. North America Opioid-Induced Respiratory Depression Market
  • 8.2.1. U.S. Opioid-Induced Respiratory Depression Market
    • 8.2.1.1. Product Type estimates & forecasts, 2018-2028
    • 8.2.1.2. End User estimates & forecasts, 2018-2028
  • 8.2.2. Canada Opioid-Induced Respiratory Depression Market
• 8.3. Europe Opioid-Induced Respiratory Depression Market Snapshot
  • 8.3.1. U.K. Opioid-Induced Respiratory Depression Market
  • 8.3.2. Germany Opioid-Induced Respiratory Depression Market
  • 8.3.3. France Opioid-Induced Respiratory Depression Market
  • 8.3.4. Spain Opioid-Induced Respiratory Depression Market
  • 8.3.5. Italy Opioid-Induced Respiratory Depression Market
  • 8.3.6. Rest of Europe Opioid-Induced Respiratory Depression Market
• 8.4. Asia-Pacific Opioid-Induced Respiratory Depression Market Snapshot
  • 8.4.1. China Opioid-Induced Respiratory Depression Market
  • 8.4.2. India Opioid-Induced Respiratory Depression Market
  • 8.4.3. Japan Opioid-Induced Respiratory Depression Market
  • 8.4.4. Australia Opioid-Induced Respiratory Depression Market
  • 8.4.5. South Korea Opioid-Induced Respiratory Depression Market
  • 8.4.6. Rest of Asia Pacific Opioid-Induced Respiratory Depression Market
• 8.5. Latin America Opioid-Induced Respiratory Depression Market Snapshot
  • 8.5.1. Brazil Opioid-Induced Respiratory Depression Market
  • 8.5.2. Mexico Opioid-Induced Respiratory Depression Market
• 8.6. Rest of The World Opioid-Induced Respiratory Depression Market

Chapter 9. Competitive Intelligence

• 9.1. Top Market Strategies
• 9.2. Company Profiles
  • 9.2.1. Medtronic Plc.
    • 9.2.1.1. Key Information
    • 9.2.1.2. Overview
    • 9.2.1.3. Financial (Subject to Data Availability)
    • 9.2.1.4. Product Summary
    • 9.2.1.5. Recent Developments
  • 9.2.2. Smiths Group
  • 9.2.3. Masimo Corporation
  • 9.2.4. Nihon Kohden Corporation
  • 9.2.5. Covidien, GE Healthcare
  • 9.2.6. Welch Allyn
  • 9.2.7. Becton
  • 9.2.8. Dickinson and Company
  • 9.2.9. BioMed Jena GmbH
  • 9.2.10. Hill-Rom, Inc.

Chapter 10. Research Process

• 10.1. Research Process
  • 10.1.1. Data Mining
  • 10.1.2. Analysis
  • 10.1.3. Market Estimation
  • 10.1.4. Validation
  • 10.1.5. Publishing
• 10.2. Research Attributes
• 10.3. Research Assumption